Financial Comparison: CONMED (NASDAQ:CNMD) & Trimedyne (NASDAQ:TMED)

CONMED (NASDAQ:CNMD) and Trimedyne (OTCMKTS:TMED) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Dividends

CONMED pays an annual dividend of $0.80 per share and has a dividend yield of 0.8%. Trimedyne does not pay a dividend. CONMED pays out 36.7% of its earnings in the form of a dividend.

Risk & Volatility

CONMED has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500. Comparatively, Trimedyne has a beta of -1.19, meaning that its share price is 219% less volatile than the S&P 500.

Institutional and Insider Ownership

96.8% of CONMED shares are owned by institutional investors. 4.4% of CONMED shares are owned by company insiders. Comparatively, 11.1% of Trimedyne shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares CONMED and Trimedyne’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CONMED $859.63 million 3.16 $40.85 million $2.18 44.05
Trimedyne $5.57 million 0.08 $230,000.00 N/A N/A

CONMED has higher revenue and earnings than Trimedyne.

Profitability

This table compares CONMED and Trimedyne’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CONMED 3.13% 9.95% 4.31%
Trimedyne 2.24% N/A N/A

Analyst Ratings

This is a summary of current ratings and recommmendations for CONMED and Trimedyne, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CONMED 0 1 3 0 2.75
Trimedyne 0 0 0 0 N/A

CONMED presently has a consensus target price of $94.75, suggesting a potential downside of 1.32%. Given CONMED’s higher probable upside, equities research analysts plainly believe CONMED is more favorable than Trimedyne.

Summary

CONMED beats Trimedyne on 12 of the 14 factors compared between the two stocks.

About CONMED

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures worldwide. The company offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, plastic, ENT, neurological, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products. It offers orthopedic surgery products under Hall, CONMED Linvatec, Concept, and Shutt brands. The company also offers general surgery product in the areas of advanced surgical comprising clinical insufflation system; electrosurgical products; endomechanical products comprising instruments, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors; and VCARE uterine manipulator for enhancing the efficiency of laparoscopic hysterectomies and other gynecologic laparoscopic procedures. In addition, it offers endoscopic technologies offering, including diagnostic and therapeutic products for use in gastroenterology procedures; cardiology and critical care products cover a line of vital signs, cardiac monitoring, and patient care products, including ECG electrodes and accessories, cardiac defibrillation and pacing pads, and suction instruments and tubing; and physician's office electrosurgical product used by dermatologists. The company markets its products directly to surgeons, hospitals, surgery centers, group purchasing organizations, integrated delivery networks, and other customers, as well as through medical specialty distributors. CONMED Corporation was founded in 1970 and is headquartered in Utica, New York.

About Trimedyne

Trimedyne, Inc. manufactures and sells lasers, and disposable and reusable fiber-optic laser devices for use in the medical field. It offers lasers, fibers, needles, and switch tips for use in orthopedics, urology, ear and nose surgery, throat surgery, gynecology, gastrointestinal surgery, general surgery, and other medical specialties. The company also provides 80 watt and 30 watt holmium lasers, and side firing laser needles to treat herniated or ruptured spinal discs. In addition, it engages in the provision of services, and rental of lasers and other medical equipment to hospitals and surgery centers on a fee-per-case basis. The company operates in Asia, Europe, Latin America, the Middle East, Australia, and internationally. It markets its products through commission sales representatives in the United States and independent distributors internationally. Trimedyne, Inc. was founded in 1980 and is based in Irvine, California.

Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit